Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
161.50    -11.00 (-6.38%)
Bid:
158.50
Ask:
162.50
Spread: 4.00 (2.524%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Blocklisting Six Monthly Return

30 Dec 2013 07:00

RNS Number : 5294W
Hutchison China Meditech Limited
30 December 2013
 



 

 

 

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

 

Blocklisting Six Monthly Return

 

 

London: Monday, 30 December 2013: Chi-Med announces the following blocklisting six monthly return:

 

1.

Name of applicant:

 

Hutchison China MediTech Limited

2.

Name of scheme:

 

Hutchison China MediTech Limited Share Option Scheme

 

3.

Period of return:

 

From 29 June 2013 to 28 December 2013

 

4.

Balance under scheme from previous return:

 

1,721,279 ordinary shares of US$1 each

 

5.

The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:

 

Nil

6.

Number of securities issued/allotted under scheme during period:

Nil

7.

Balance under scheme not yet issued/allotted at end of the period:

 

1,721,279 ordinary shares of US$1 each

8.

Number and class of securities originally listed and the date of admission:

 

2,560,606 ordinary shares of US$1 each admitted on 26 June 2007

9.

Total number of securities in issue at the end of the period:

52,051,448 ordinary shares of US$1 each

Name of contact:

 

Christian Hogg

Address of contact:

 

21/F., Hutchison House, 10 Harcourt Road, Hong Kong

 

Telephone number of contact:

 

+852 2121 8200

 

 

 

Ends

 

 

 

Enquiries

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

 

Panmure Gordon (UK) Limited

Telephone: +44 20 7886 2500

Richard Gray

Andrew Potts

Grishma Patel

 

 

 

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 20 7638 9571

Mobile: +44 7973 611 888

Mobile: +44 7967 566 919

 

 

About Chi-Med

 

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

 

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited. For more information, please visit: www.chi-med.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRURVNROUAUORA
Date   Source Headline
30th Jun 20259:30 amRNSTotal Voting Rights
30th Jun 20259:30 amRNSBlocklisting Six Monthly Return
10th Jun 202511:00 amRNSGrant of Share Options and Awards under LTIP
5th Jun 20257:00 amRNS-RHUTCHMED and Innovent Announce NDA Acceptance
2nd Jun 20257:00 amRNS-RHUTCHMED Highlights SACHI Phase III Data at ASCO
30th May 20259:30 amRNSTotal Voting Rights
23rd May 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at ASCO
13th May 202511:45 amRNSAGM held on May 13, 2025 – Poll Results
24th Apr 20257:00 amRNS-RHUTCHMED - Data to be Presented at AACR 2025
22nd Apr 20257:00 amRNS-RHUTCHMED Completes Enrollment of Phase II Study
7th Apr 20259:30 amRNS2024 Annual Report and Notice of AGM
31st Mar 202510:30 amRNSExtraordinary General Meeting – Poll Results
21st Mar 202510:00 amRNS-RNMPA Conditional Approval for TAZVERIK®
20th Mar 20259:30 amRNSRetirement of Independent Non-executive Directors
20th Mar 20257:00 amRNS-RHUTCHMED Highlights Savolitinib SAVANNAH Phase II
19th Mar 20251:45 pmRNS-RPublication of Form 20-F
19th Mar 202511:00 amRNS2024 Final Results and Business Updates
19th Mar 20257:00 amRNS-RPhase II/III Study of Fruquintinib and Sintilimab
14th Mar 20259:30 amRNSAdoption of the 2025 Long Term Incentive Plan
14th Mar 20259:30 amRNSVesting of awards under Long Term Incentive Plan
13th Mar 20259:30 amRNSNotice of Extraordinary General Meeting
6th Mar 202510:00 amRNS-RCompleted Enrollment of Phase II Study
5th Mar 202510:00 amRNSDirectorate Change
3rd Mar 20257:00 amRNSOverseas Regulatory Announcement
28th Feb 20253:00 pmRNSOverseas Regulatory Announcement
19th Feb 20258:30 amRNSNotice of Results
28th Jan 20259:00 amRNSOverseas Regulatory Announcement
14th Jan 20257:00 amRNS-RFull Approval for ORPATHYS in China
2nd Jan 20257:00 amRNSOverseas Regulatory Announcement
2nd Jan 20257:00 amRNSUS$608m Divestment of Non-Core Joint Venture
31st Dec 20248:30 amRNSAppointment of Joint Corporate Broker
30th Dec 20248:30 amRNSBlocklisting Six Monthly Return
29th Nov 20248:30 amRNSTotal Voting Rights
20th Nov 20249:30 amRNSAppointment of Independent Non-executive Director
31st Oct 20248:30 amRNSTotal Voting Rights
21st Oct 20249:30 amRNSVesting of awards under the LTIP
16th Oct 20247:00 amRNSSAVANNAH: clinically meaningful response rate
24th Sep 20248:00 amRNSJapan Approval for FRUZAQLA
30th Aug 20249:30 amRNSTotal Voting Rights
30th Aug 20247:00 amRNSUpdate on Fruquintinib for Gastric Cancer in China
22nd Aug 20249:30 amRNSStandard form for notification of major holdings
6th Aug 202410:00 amRNSLTIP and Share Option Scheme
31st Jul 202412:00 pmRNS2024 Interim Results and Business Updates
28th Jun 20249:30 amRNSTotal Voting Rights
28th Jun 20249:30 amRNSBlocklisting Six Monthly Return
26th Jun 20249:30 amRNSHUTCHMED to Announce 2024 HY Financial Results
24th Jun 20247:00 amRNSEuropean Commission Approval for FRUZAQLA
7th Jun 20247:00 amRNSHUTCHMED Initiates Phase I Trial of HMPL-506
3rd Jun 20247:00 amRNSNature Medicine Publish Phase III FRUTIGA Results
31st May 20249:30 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.